Sierra Oncology (NASDAQ:SRRA) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a buy rating in a research report released on Wednesday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered shares of Sierra Oncology from a buy rating to a hold rating in a research note on Friday, August 16th.

Shares of NASDAQ SRRA traded down $0.01 during midday trading on Wednesday, hitting $0.34. The company’s stock had a trading volume of 460,302 shares, compared to its average volume of 555,141. The business’s fifty day simple moving average is $0.42 and its two-hundred day simple moving average is $0.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.24 and a quick ratio of 9.24. Sierra Oncology has a 1 year low of $0.33 and a 1 year high of $2.01. The firm has a market capitalization of $25.62 million, a price-to-earnings ratio of -0.46 and a beta of 1.28.

Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20). Analysts anticipate that Sierra Oncology will post -0.81 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of SRRA. Acadian Asset Management LLC lifted its stake in Sierra Oncology by 19.5% in the first quarter. Acadian Asset Management LLC now owns 486,493 shares of the biotechnology company’s stock worth $831,000 after acquiring an additional 79,388 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Sierra Oncology by 981.2% in the second quarter. JPMorgan Chase & Co. now owns 43,703 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 39,661 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Sierra Oncology by 22.0% in the second quarter. Renaissance Technologies LLC now owns 2,312,634 shares of the biotechnology company’s stock worth $1,295,000 after acquiring an additional 417,300 shares during the last quarter. Institutional investors own 52.28% of the company’s stock.

About Sierra Oncology

Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.

Read More: What defines an oversold asset?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.